[go: up one dir, main page]

MX2019011003A - Mutaciones de empalmosoma y usos de las mismas. - Google Patents

Mutaciones de empalmosoma y usos de las mismas.

Info

Publication number
MX2019011003A
MX2019011003A MX2019011003A MX2019011003A MX2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A MX 2019011003 A MX2019011003 A MX 2019011003A
Authority
MX
Mexico
Prior art keywords
mutations
spliceosome
methods
treatment
spliceosome mutations
Prior art date
Application number
MX2019011003A
Other languages
English (en)
Inventor
Zhu Ping
Puyang Xiaoling
Warmuth Markus
Teng Teng
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019011003A publication Critical patent/MX2019011003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen aquí mutaciones del empalmosoma que incluyen mutaciones en las subunidades PHF5A Y SF3B1. Esta solicitud también describe la detección de la presencia y/o ausencia de mutaciones en el empalmosoma, y también métodos de diagnóstico de la responsividad al tratamiento con modulador de empalme, métodos de tratamiento de trastornos neoplásicos y métodos de monitoreo o alteración de tratamiento, basados en el estado de las mutaciones.
MX2019011003A 2017-03-15 2018-03-14 Mutaciones de empalmosoma y usos de las mismas. MX2019011003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471903P 2017-03-15 2017-03-15
PCT/US2018/022437 WO2018170129A1 (en) 2017-03-15 2018-03-14 Spliceosome mutations and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011003A true MX2019011003A (es) 2019-12-16

Family

ID=61868877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011003A MX2019011003A (es) 2017-03-15 2018-03-14 Mutaciones de empalmosoma y usos de las mismas.

Country Status (13)

Country Link
US (1) US20200190593A1 (es)
EP (1) EP3596235A1 (es)
JP (1) JP2020514348A (es)
KR (1) KR20190137810A (es)
CN (1) CN110914457A (es)
AU (1) AU2018235940A1 (es)
BR (1) BR112019019092A2 (es)
CA (1) CA3056389A1 (es)
IL (1) IL268932A (es)
MX (1) MX2019011003A (es)
RU (1) RU2019132208A (es)
SG (1) SG11201907887SA (es)
WO (1) WO2018170129A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI853863B (zh) 2018-12-13 2024-09-01 日商衛材R&D企管股份有限公司 荷伯希二烯(herboxidiene)剪接調節抗體-藥物結合物及其使用方法
CN113384703B (zh) * 2021-06-21 2023-03-10 深圳市第二人民医院(深圳市转化医学研究院) Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU703922B2 (en) 1995-12-28 1999-04-01 Kyowa Hakko Kogyo Co. Ltd. Compound gexi
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
WO2004011459A1 (ja) 2002-07-31 2004-02-05 Mercian Corporation 新規生理活性物質
KR101285695B1 (ko) 2002-07-31 2013-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 생리 활성 물질
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
US7932083B2 (en) 2003-11-27 2011-04-26 Mercian Corporation DNA participating in hydroxylation of macrolide compound
ATE538203T1 (de) 2004-07-20 2012-01-15 Eisai R&D Man Co Ltd Für an der biosynthese von pladienolid beteiligtes polypeptid codierende dna
CN102010403A (zh) 2005-10-13 2011-04-13 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
US7999080B2 (en) * 2006-07-13 2011-08-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
AU2007340265B2 (en) * 2006-09-19 2012-07-26 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for Raf inhibitors
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20150025017A1 (en) * 2012-02-28 2015-01-22 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
EP2917195B9 (en) 2012-11-05 2018-05-30 Pfizer Inc Spliceostatin analogs
TWI634115B (zh) * 2014-05-15 2018-09-01 Eisai R&D Management Co., Ltd. 普拉二烯內酯吡啶化合物及其使用方法
EP3344780B1 (en) * 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants

Also Published As

Publication number Publication date
BR112019019092A2 (pt) 2020-06-30
CN110914457A (zh) 2020-03-24
RU2019132208A3 (es) 2021-04-15
IL268932A (en) 2019-10-31
AU2018235940A1 (en) 2019-10-17
KR20190137810A (ko) 2019-12-11
SG11201907887SA (en) 2019-09-27
RU2019132208A (ru) 2021-04-15
EP3596235A1 (en) 2020-01-22
WO2018170129A1 (en) 2018-09-20
JP2020514348A (ja) 2020-05-21
CA3056389A1 (en) 2018-09-20
US20200190593A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
TN2019000165A1 (en) (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides
ZA201803366B (en) Antibody molecules to april and uses thereof
EP3685286C0 (en) EMAIL-BASED AUTHENTICATION FOR ACCOUNT LOGIN, ACCOUNT CREATION, AND SECURITY FOR PASSWORDLESS TRANSACTIONS
BR112017006664A2 (pt) terapias de combinação
CY1121529T1 (el) Σηματοδοτηση slit-robo για διαγνωση και θεραπεια νεφρικης νοσου
BR112018070133A2 (pt) dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos
EP3532891A4 (en) DEVICES, SYSTEMS AND / OR METHODS FOR CONTROLLING SHORT-VISION
MX383652B (es) Moduladores de la vía de estrés integrada.
MX2018012476A (es) Sistemas y metodos para determinar falla de dispositivos intragastricos.
BR112019003172A2 (pt) frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MA40249A (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
EP3110974A4 (en) Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
MX376201B (es) Compuestos inhibidores de metaloenzima.
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
WO2016040824A3 (en) METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USE OF SAME TO MODULATE mTORC1
BR112018006986A2 (pt) métodos e composições para contrações musculares indesejadas ou anormais
EP4487912A3 (en) Improved treatment of atopic dermatitis with tradipitant
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
EA201592265A1 (ru) Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения